Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer

✍ Scribed by David M. O'Malley; Debra L. Richardson; Patrick S. Rheaume; Ritu Salani; Eric L. Eisenhauer; Georgia A. McCann; Jeffrey M. Fowler; Larry J. Copeland; David E. Cohn; Floor J. Backes

• Book ID: 113963094
• Publisher: Elsevier Science
• Year: 2011
• Tongue: English
• Weight: 249 KB
• Volume: 121
• Category: Article
• ISSN: 0090-8258
• DOI: 10.1016/j.ygyno.2011.01.009